Researchers reported that a next‑generation live attenuated oral poliovirus type 2 vaccine (nOPV2) exhibits improved genetic stability compared with earlier strains when challenged by neurovirulent variants. The findings, published in a peer‑reviewed study, indicate fewer reversion events and a favorable safety profile in preclinical assessments. Given ongoing poliovirus outbreaks and concerns about vaccine‑derived poliovirus, enhanced stability could strengthen eradication campaigns by reducing the risk of reversion. The study detailed genomic analyses and back‑mutation rates under selective pressure to support the stability claim. Public‑health agencies and vaccine manufacturers will weigh these data as they plan distribution and manufacturing of next‑generation OPV candidates for use in endemic and outbreak settings.